What is Critical Limb Ischemia?
Critical Limb Ischemia is the advanced stage of peripheral artery disease (PAD), which results from a progressive thickening of an artery’s lining (caused by a buildup of plaque). This buildup of plaque, also known as atherosclerosis, narrows or blocks blood flow, reducing circulation of blood to the legs, feet, or hands.
How many people are affected by Critical Limb Ischemia?
- According to DelveInsight’s findings, males are affected more by Critical Limb Ischemia as compared to females.
- There are approximately 6.5 million patients with Critical Limb Ischemia in the US, Europe, and Japan based on global population-based studies.
- Critical Limb Ischemia account for only between 1% and 3% of all patients with PAD, with an incidence of between 500 and 1000 per million persons per year in Europe and North America.
Request for free sample pages @ Critical Limb Ischemia Market Size
How will Critical Limb Ischemia Market change in upcoming years?
Critical Limb Ischemia market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies and incremental healthcare spending across the world.
The drugs in the clinical trials are expected to propel the growth of the Critical Limb Ischemia drugs market in the upcoming years.
Critical Limb Ischemia Emerging Therapies
Of the emerging therapies, the most anticipated product to get launched is PLX-PAD. Apart from this, several other molecules are in mid to late stage such as Rejuveinix, ACP-01 and others.
The key players like Libella Gene Therapeutics, Hemostemix, Pluristem, Reven Pharma and others have the potential to create a significant positive shift in the Critical Limb Ischemia market size.
Request for free sample pages @ Critical Limb Ischemia Market Size
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/